Beckman Coulter Diagnostics appoints Catherine Jennings as president

Beckman Coulter Diagnostics, a subsidiary of Danaher Corporation (NYSE: DHR), announced the appointment of Catherine "Cat" Jennings as president, according to a company statement.

Jennings joins from Boston Scientific, where she most recently served as president of Vascular Therapies, overseeing a global business with approximately $2 billion in annual revenue. She brings more than 20 years of healthcare industry experience.

In her new role, Jennings will oversee the company's strategic, operational and organizational priorities. Beckman Coulter Diagnostics is headquartered in Brea, Calif., and employs more than 10,000 people worldwide.

Kevin O'Reilly, Group Executive of Danaher Diagnostics, said in the statement: "Cat's leadership will help us accelerate innovation and expand the impact of diagnostic solutions around the world."

Jennings holds a Bachelor of Science in Biology from Georgetown University and a Master of Business Administration from the University of California, Los Angeles.

You May Also Be Interested In

• Danaher and Nvidia partner to integrate AI into lab instruments
• Danaher (DHR) PT Raised to $240 at Morgan Stanley
• Beckman Coulter Diagnostics Names Catherine Jennings as President